To analyze the value of real time RT-PCR for monitoring of bcrabl expression in CML patients after allogeneic or autologous stem cell transplantation (SCT), we generated pairs of PCR-primers and TaqMan probes specific for either the b2a2-or the b3a2-variant of bcr-abl. Either variant could be detected specifically from cDNA from a single K562 (b3a2) and BV173 (b2a2) cell with the respective TaqMan probe. Bcr-abl expression was normalized by comparison with GAPDH expression, and samples were quantitated using standard cDNA dilutions from K562 or BV173 cells. In a retrospective analysis 13 patients with CML after allogeneic (n = 10) or autologous (n = 3) SCT including patients with relapsed or persistent CML were analyzed by both real-time and conventional nested RT-PCR. In addition chimerism was monitored by FISH analysis of sex chromosomes in three patients with relapsed disease. The bcr-abl/GAPDH ratio dropped at least 1000-fold in all seven patients evaluable prior to and after allogeneic SCT as estimated by real-time RT-PCR, and conventional RT-PCR became negative in 6/7 patients. In five patients with relapsed or persistent disease after allogeneic SCT the bcr-abl/GAPDH ratio eventually increased again, and real-time RT-PCR was as sensitive as conventional RT-PCR for detection of bcr-abl. Donor lymphocyte infusions (DLI) were given to all five patients, and the bcr-abl/GAPDH ratio dropped to undetectable levels in two patients both remaining in continuing molecular remission. In contrast, in three other patients the bcrabl/GAPDH ratio decreased only or did not change significantly after DLI. In three patients undergoing autologous SCT the bcrabl/GAPDH ratio dropped only 1.1 to 30-fold, and the patients were tested positive with real-time RT-PCR at all time points. These data demonstrate that real-time RT-PCR is valuable to quantitate bcr-abl expression in CML patients after transplantation.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disorder of a pluripotent hematopoietic stem cell characterized by the chimeric bcr-abl gene resulting from the juxtaposition of abl-sequences from chromosome 9 to the bcr-gene on chromosome 22 in more than 95% of all patients. 1 The corresponding cytogenetic hallmark is the Ph-chromosome with t(9;22)(q34;q11). CML is a bi-or triphasic disease with an initial stable or chronic phase followed ultimately by either an accelerated phase or directly by blast crisis terminating fatally. Actual therapeutic options include busulfan, hydroxyurea (HU), IFN-␣, Ara-C, and allogeneic or autologous bone marrow (BMT) or peripheral blood stem cell transplantation (PBSCT). [2] [3] [4] [5] [6] [7] [8] [9] Whereas HU and IFN-␣ given in chronic phase can prolong survival, allogeneic stem cell transplantation (SCT) is believed to be the only curative therapy so far. For patients relapsed after allogeneic SCT donor lymphocyte Correspondence: M Eder; Fax: 49 511 532 3611 Received 9 February 1999; accepted 19 May 1999 infusions (DLI) initiating a graft-versus-leukemia (GVL) effect can induce long lasting molecular remission and probably cure. 10 To monitor the disease and to evaluate the efficacy of therapeutic regimens, hematologic parameters, cytogenetics of Ph+ cells, and expression analysis of bcr-abl using RT-PCR including competitive semiquantitative RT-PCR assays are currently performed. The increase of bcr-abl expression after allogeneic SCT has especially been shown to be predictive for relapse. 11, 12 However, a sensitive, quantitative, and routine setting RT-PCR is not currently established for monitoring the course of CML but could be helpful in individual decisionmaking concerning the best therapeutic option. We therefore analyzed the value of real-time TaqMan RT-PCR in CML patients after allogeneic or autologous SCT. Real-time TaqMan PCR technology uses the ability of Taq-polymerase to displace and hydrolyze a fluorescence-labelled reporter oligonucleotide annealed to a target sequence during PCR amplification (5Ј nuclease PCR assay, [13] [14] [15] for review see Ref. 16 ). This enables the generation of a specific fluorescence signal upon excitation that can be followed real-time on a per cycle base allowing the quantitation of the initial copy number per sample.
We show here in a retrospective analysis of 13 patients after either allogeneic or autologous SCT that the normalized bcrabl expression can be quantitated over time with appropriate pairs of PCR primers and TaqMan probes in CML after SCT. Both allogeneic and autologous SCT and DLI can lower the bcr-abl/GAPDH ratio, and real-time RT-PCR is at least as sensitive as conventional RT-PCR in detecting bcr-abl expression.
Materials and methods

Patients
cDNA samples from 18 patients referred to our institution for SCT or DLI treatment were analyzed for bcr-abl expression by both conventional RT-PCR and real-time RT-PCR. For 13/18 patients probes were analyzed after SCT, whereas for five patients no samples were available after SCT. Patients BF and BH were not transplanted at our institution. From the 13 patients evaluable after transplantation eight received allogeneic transplants (PBSCT n = 7, BMT n = 1) from HLA-identical siblings after conditioning with total body irradiation (TBI)/cyclophosphamide (n = 2) or busulfan/cyclophosphamide (n = 5) or busulfan/cyclophosphamide/thiotepa (n = 1). One patient was treated with busulfan/ cyclophosphamide and underwent BMT from an unrelated HLA-identical donor, and one obtained PBSCT from her syngeneic twin after conditioning with TBI/cyclophosphamide. Three patients received autologous PBSCT after conditioning with busulfan only.
From all 18 patients analyzed at any time prior to or after SCT, 15 patients expressed the b2a2-variant, and three the b3a2-variant of bcr-abl. None of the patients expressed both variants simultaneously as determined by conventional nested RT-PCR shown to be capable of detecting the stimultaneous presence of both variants. All samples analyzed were from peripheral blood mononuclear cells if not stated otherwise.
RNA isolation, cDNA synthesis
Total RNA was extracted with Trizol (Gibco BRL, Life Technologies, Karlsruhe, Germany) from 10 6 to 10 7 peripheral blood or bone marrow mononuclear cells after density centrifugation using Ficoll-Hypaque. RNA was transcribed into cDNA in a 20 l reaction initially with AMV-RT and later, because of higher yields, with MMLV-reverse transcriptase using random hexamer primers under standard conditions.
Conventional nested RT-PCR
The conventional nested RT-PCR was performed as described by Maurer et al. 17 The amplification from the b2a2 variant and the b3a2 variant result in amplica of 320 bp and 395 bp, respectively.
Generation of PCR primers and TaqMan probes for real-time RT-PCR
The PCR-primers and TaqMan probes to amplify and detect the b2a2 and the b3a2 variant of bcr-abl were designed using the Primer Express software version 1.0 (Perkin Elmer/Applied Biosystems, Foster City, USA) as follows: b2a2 sense: tgtgaaactccagactgtccaca (Tm 59°C), b2a2 antisense: aaagtcagatgctactggccg (Tm 58°C), b3a2 sense: tccactcagccactggatttaa (Tm 58°C), b3a2 antisense: tgaggctcaaagtcagatgctact (Tm 58°C). The PCR primers were purchased from Pharmacia (Uppsala, Sweden). The TaqMan probes were placed to cover the fusion region of the b2a2 and b3a2 variant, respectively. The probes b2a2: tgaccatcaataaggaagaagcccttcagc (Tm 69°C) and b3a2: cagagttcaaaagcccttcagcggc (Tm 69°C) were purchased labeled with 6-carboxy-fluorescein (FAM) as the reporter dye and 6-carboxy-tetramethyl-rhodamine (TAMRA) as the quencher fluorescent (Perkin Elmer/Applied Biosystems, Weiterstadt, Germany). The TaqMan probes were 3Ј phosphorylated in order to prevent elongation during PCR. The TaqMan-GAPDH Control Reagents (Perkin Elmer/Applied Biosystems) were used to amplify and detect GAPDH as recommended by the manufacturer.
Real-time PCR
Real-time PCR was performed on an ABI PRISM 7700 Sequence Detector, using the ABI PRISM 7700 Sequence Detector Software 1.6 (Perkin Elmer/Applied Biosystems). Optimal reaction conditions for amplification of both GAPDH and bcr-abl were as follows: 40 cycles of a two-step PCR (95°C 15 s, 60°C 60 s) after initial denaturation (95°C for 
Normalization and quantitation
According to an initial conventional RT-PCR analysis for the presence of either bcr-abl variant the appropriate TaqMan probe/PCR primer set was chosen for real-time RT-PCR analysis for all patients. For quantitation bcr-abl expression was normalized by comparison with GAPDH expression. Bcr-abl and GAPDH expression were quantitated using standard cDNA dilutions freshly prepared for every analysis from a stock solution corresponding to 10 4 BV173 (b2a2) and K562 (b3a2) cells, respectively. The standard dilutions included at least five values spanning five orders of magnitude with r Ͼ 0.97 in all cases. Each standard and sample value was determined in triplicates in all but one patient (duplicates). If a cDNA sample expressed GAPDH corresponding to fewer than 100 BV173 and K562 cells, respectively, the sample was excluded from further analysis (n = 8 after reverse transcription with AMV-RT). The bcr-abl/GAPDH ratio was calculated as number of reference cells expressing equal amounts of the corresponding bcr-abl variant divided by the number of reference cells expressing equal amounts of GAPDH. Therefore the expected value for the bcr-abl/GAPDH ratio for a sample of the reference cells lines BV173 and K562 is one.
FISH analysis of sex chromosomes
Fluorescence in situ hybridization was performed after fixing in methanol/glacial acetic acid (4:1) and hybridization in Cep Hybrid buffer (Vysis, Stuttgart, Germany) at 37°C overnight with the X-and Y-chromosome specific probes Spectrum Green and Spectrum Orange, respectively (Vysis).
Results
Specific and sensitive detection of bcr-abl variants using real-time RT-PCR
To detect specifically the b2a2 and the b3a2 variant of bcrabl we generated TaqMan probes covering the b2a2 and the b3a2 fusion sequence, respectively. Using the corresponding pairs of PCR primers amplification from the b2a2 and b3a2 templates result in amplica of 82 and 73 bp, respectively. When cDNAs from BV 173 (b2a2) and K 562 (b3a2) cells were prepared and serially diluted, bcr-abl was detectable in the cDNA corresponding to a single cell for both variants by both real-time and conventional nested RT-PCR ( Figure 1 ). Further dilution corresponding to the amount of cDNA of 0.5 and 0.1 BV173 cells resulted in specific detection of bcr-abl in 8/9 and 5/18 analyses by real-time RT-PCR, respectively (data not shown). The same cDNA samples were tested positive in 2/2 and 0/2 experiments by conventional RT-PCR, respectively ( Figure 1 and data not shown). It should be noted that the b2a2 pair of PCR primers also enables the amplification of sequences from the b3a2 template. However, specific detection of the b3a2 variant is obtained by the specificity of the TaqMan probe. To assure specific detection of either variant, cDNA from both BV173 and K562 cells was analyzed using the primer pairs/TaqMan probes designed to detect either the b2a2 or b3a2 variant. As expected specific detection was only achieved for BV173 cDNA with the b2a2 (but not the b3a2), and for K562 cDNA with the b3a2 (but not the b2a2) TaqMan probe at the highest cDNA concentration tested (cDNA from 10 5 cells, data not shown). 
Accuracy of real-time RT-PCR quantitation and correlation with cytogenic analysis
To determine the accuracy of quantitation depending on the amount of cDNA per sample, we analyzed the bcrabl/GAPDH ratio in the cDNA from 10 2 to 10 4 BV173 cells. In five independent experiments the mean bcr-abl/GAPDH ratio was 0.90 (10 2 cells, coefficient of variation (cv) = 0.254), 0.98 (10 3 cells, cv = 0.292), and 1.06 (10 4 cells, n = 4, cv = 0.276), respectively. In addition to cDNA from BV173 cells, cDNA samples from two CML patients were quantitated twice as follows: identical cDNA samples obtained at different time points during the disease were prepared for and analyzed by real time RT-PCR in two independent experiments. For the first patient the difference of the bcr-abl/GAPDH ratio in eight samples quantitated in two independent TaqMan analyses was between 6.0% and 71.1% (mean difference 29.6%). For the second patient the bcr-abl/GAPDH ratios differed from 10.8% to 61.0% (mean difference 30.9%) between two independent real-time quantiations of cDNA samples from five different time points (data not shown).
Samples from five patients were available for both analysis of Ph+ metaphases and real-time RT-PCR quantitation. As shown in Table 1 , Ph-positive metaphases were detected in seven out of nine samples with a minimal bcr-abl/GAPDH ratio of 0.250. In contrast only Ph-negative metaphases were found in two samples with bcr-abl/GAPDH ratios of 0.002 and 0.003, respectively.
Bcr-abl expression prior to transplantation
Prior to SCT, samples from 15 patients were available for quantitation of bcr-abl expression (Table 2a and b) . For patients with more than one sample available prior to SCT the quantitation of the first probe taken at our institution is given 
Bcr-abl expression after allogeneic transplantation
From 10 patients analyzed after allogeneic SCT, five became negative for bcr-abl expression after SCT as determined by both conventional and real-time RT-PCR. All analyses from these patient samples at different time points were tested negative by both PCR methods (n = 25), and all patients remained Patients listed in Table 2 were analyzed both prior to and after SCT. The upper seven patients received allogeneic SCT, whereas the lower three underwent autologous PBSCT. PB, peripheral blood; BM, bone marrow; HU, hydroxyurea; IFN, interferon-␣. For patients listed in Table 2b , no samples were available after SCT. PB, peripheral blood; BM, bone marrow; HU, hydroxyurea; IFN, interferon ␣. After therapy with Ara-C, vincristine, mitoxantrone for blast crisis.
in molecular remission after allogeneic SCT so far (data not shown).
Five patients with relapsed (n = 4) or persistent (n = 1) CML after allogeneic SCT were selected for analysis of bcr-abl expression at multiple time points after SCT (Table 3 ). In those patients the bcr-abl/GAPDH ratio dropped at least 1000-fold or bcr-abl became undetectable after SCT. In UPN 378 (male) the bcr-abl/GAPDH ratio decreased from 8.65 to 0.002 at 4 weeks after allogeneic PBSCT from an HLA-identical sister. At the same time point, 3/300 peripheral blood cells had an XY karyotype as determined by FISH analysis. The bcrabl/GAPDH ratio increased to maximal 5.538 (2770-fold increase) 17 weeks after PBSCT with a concomitant increase of autologous hematopoiesis (145 XY/300 cells). DLI (5 × 10 6 and 1 × 10 7 T-lymphocytes per kg) were given 12 and 17 weeks after PBSCT, and the bcr-abl/GAPDH ratio decreased from 1.526 at 22 weeks to become 0 at 32 weeks after SCT. In parallel, chimerism turned to donor origin with 100% XX mononuclear cells at the same time. The patient has remained in continuing molecular remission without therapy as determined by both real-time and conventional RT-PCR (four consecutive time points, 32 months after PBSCT, data not shown).
Patient BF presented at our institution 3 years after allogeneic BMT with 44 900/nl leukocytes under therapy with hydroxyurea with a bcr-abl/GAPDH ratio of 0.476. A total of seven DLI in increasing doses (5 × 10 6 to 5 × 10 7 T-lymphocytes per kg) were given in 6 months, and the bcr-abl/GAPDH ratio decreased from maximal 26.088 to 0 at 2 months after the last DLI. In parallel the patient developed GVHD and the peripheral blood leukocytes dropped to 0.800/nl, but finally recovered, and the patient is in continuing molecular remission as determined by both conventional and real-time RT-PCR 59 months after transplantation (four consecutive time points, data not shown).
In UPN 408 with persisting disease the bcr-abl/GAPDH ratio dropped from 3.93 to 0.002 at about 7 weeks after allogeneic PBSCT from an HLA-identical sister. At the same timepoint 54/300 cells exhibited a XY-karyotype as determined by FISH analysis, and conventional RT-PCR was positive all the time. The bcr-abl/GAPDH ratio increased to maximal 16.404, and four DLI in increasing doses (5 × 10 6 to 1 × 10 8 T-lymphocytes per kg) were given over a period of 4 months. However, the bcr-abl/GAPDH ratio increased further to a maximum of 28.588, and the patient had 100% autologous hematopoiesis from about 1 year after PBSCT. He has currently stable disease 27 months after transplantation.
UPN 373 was transplanted in second chronic phase after lymphoid blast crisis. He tested negative for bcr-abl expression by both conventional and real-time RT-PCR for up to 8 months after allogeneic PBSCT at seven consecutive time points. Thereafter bcr-abl became detectable, and the bcrabl/GAPDH ratio increased from 0.054 to 2.917 in 6 months. The patient relapsed with lymphoid blast crisis and received one DLI (1 × 10 7 T-lymphocytes per kg) 3 months after treatment with mitoxantrone. However the patient did not respond and died 6 weeks later.
In UPN 379 (female) the bcr-abl/GAPDH ratio dropped from 0.774 before to undetectable levels after PBSCT from an HLA-identical brother as determined by both conventional and real-time RT-PCR for at least 7 months (analysis at five different time points). Thereafter bcr-abl became detectable several times by both PCR methods but disappeared again 
Bcr-abl expression after autologous transplantation
Three patients were analyzed for quantitative bcr-abl expression after conditioning with busulfan and autologous PBSCT ( Table 4 ). The bcr-abl/GAPDH ratio dropped about 30- Time is given in weeks after auto-PBSCT.
fold in two patients (UPN 462, UPN 403) , and about 1.1-fold in the third patient (UPN 432). The leukaphereses used for transplantation expressed a bcr-abl/GAPDH ratio lower than 0.06 in the first two patients, but was quantitated between 0.40 and 0.72 for the third patient (data not shown). After PBSCT all three patients were tested positive by conventional and real-time RT-PCR. From a total of nine analyses, one conventional RT-PCR was negative whereas real-time RT-PCR gave a bcr-abl/GAPDH ratio of 0.062 (UPN 462). In this patient the bcr-abl/GAPDH ratio remained between 0.062 and 0.163 over a period of 46 weeks after auto-PBSCT. He is currently in hematologic remission under therapy with IFN-␣ 20 months after transplantation. UPN 403 had bcr-abl/GAPDH ratios between 0.003 and 0.250 in the peripheral blood up to 23 weeks after PBSCT and is currently in hematologic remission 28 months after PBSCT. The bcr-abl/GAPDH ratio for UPN 432 was between 1.181 and 1.325 in the peripheral blood for up to 71 weeks after PBSCT. The patient now has stable disease under therapy with hydroxyurea 2 years after SCT.
Discussion
We report here the quantitation of bcr-abl expression in mononuclear cells from CML patients before and after allogeneic or autologous SCT using real-time RT-PCR. We demonstrate that this method is as sensitive as conventional nested RT-PCR for the detection of bcr-abl in both cell lines and patient samples with a detection limit corresponding to the cDNA of a single BV173 or K562 cell. In addition the quantitation by real-time RT-PCR is reproducible with a mean error in our hands of about 30% when identical cDNA samples were quantitated twice in two different TaqMan PCR analyses. Prior to SCT, bcr-abl was detectable in all cases by both PCR methods, and the bcr-abl/GAPDH ratio was between 0.067 and 8.653 in 15 patients analyzed. There was no correlation between the normalized bcr-abl expression and the total peripheral blood leukocyte count including patients under cytoreductive therapy. In contrast, cytogenetic analysis demonstrated Ph-positive metaphases in seven out of nine samples with a minimal bcr-abl/GAPDH ratio of 0.250, whereas Phnegative metaphases only were found in two samples with bcr-abl/GAPDH ratios of 0.003 or less. As confirmed by conventional nested RT-PCR bcr-abl/GAPDH ratios as low as 2 × 10 −3 represent a positive signal for bcr-abl expression. These data suggest a correlation between the number of Phpositive metaphases and an increasing bcr-abl/GAPDH ratio but the limited sample number has to be considered.
After allogeneic SCT the bcr-abl/GAPDH ratio dropped to 0 or at least more than 1000-fold in all patients analyzed including one with persistent disease after allogeneic PBSCT. Interestingly, the bcr-abl/GAPDH ratio decreased only 1.1-30-fold in three patients after autologous PBSCT after conditioning with busulfan. This difference in the efficacy between allogeneic and autologous SCT is most likely due to the reconstitution of a bcr-abl negative hematopoiesis in patients after allogeneic SCT. Whether different conditioning regimens contribute to the different efficacy is currently not known. Although only three patients were analyzed after identical conditioning it is interesting to note that the two patients with 30-fold decrease in the bcr-abl/GAPDH ratio received transplants with 10-fold lower bcr-abl/GAPDH ratio than the patient with almost no change of bcr-abl expression after auto-PBSCT.
In the five patients with relapse or persistent disease after allogeneic SCT, bcr-abl remained or became detectable by both conventional and real-time RT-PCR at about the same time in all cases. A shift in mixed chimerism as measured by FISH analysis of sex chromosomes with an increase of autologous hematopoiesis paralleled the rise of the normalized bcr-abl expression in three evaluable patients. DLI were given to all five patients with persistent disease or relapse, and the bcr-abl/GAPDH ratio dropped finally to undetectable levels in two patients 8 and 15 weeks after the last DLI, but decreased only temporarily or changed less than 10-fold in three other patients. One of these patients with bad response to DLI is still under treatment with increasing cell doses after a first DLI, and one received DLI for relapse of lymphoid blast crisis. These data correspond to a recent study by Baurmann et al 18 who report the kinetics of GVL effects after DLI in three patients with relapsed CML after allogeneic SCT. Between 9 to 18 weeks after DLI all three patients examined achieved a molecular remission. Mensink et al 19 first reported the use of real-time RT-PCR in CML patients after allogeneic SCT. They also found a decrease and final disappearance of bcr-abl expression after DLI in three patients with relapsed CML. They also demonstrate the disappearance of Ph-positive metaphases with decreasing bcr-abl expression. However, there are some differences to our study. We used PCR-primer/TaqMan probes specific for either the b2a2 and the b3a2 bcr-abl variant and TaqMan probes located close to the 5ЈPCR primer in order to maximize the efficacy of the TaqMan PCR. In addition we compared real-time RT-PCR with a conventional non-quantitative nested RT-PCR and found a high correspondence between the two PCR methods. Only two samples were tested negative by conventional but positive by real-time RT-PCR whereas all samples tested positive by means of conventional RT-PCR were also tested positive with real-time RT-PCR. In contrast to GAPDH, Mensink et al 19 use PBGD for normalization. No standard housekeeping gene for RNA normalization in hematopoietic cells has been established so far, and some variation of gene expression depending on exogeneous stimuli has been described for example in thyroid cells. 20 In a recent study 21 we have analyzed the differential quantitation of similar target sequences by TaqMan PCR technology in detail by mixing cDNA from alternatively spliced mRNAs. We found precise quantitation of either isoform even in the presence of a 100-fold excess of the alternative variant using isoform specific TaqMan probes. Accordingly, when cDNA from BV173 and K562 cells was mixed, either variant could be differentially quantitated with the appropriate Taq-Man probe even in the presence of the alternative isoform (data not shown). Therefore the use of separate TaqMan probes for the b2a2 and the b3a2 variant of bcr-abl allows the independent quantitation of either isoform and may allow the monitoring of clonal evolution in CML patients expressing both the b2a2 and the b3a2 variant. However, bcr-abl fusions different from b2a2 and b3a2 can not be quantitated with the TaqMan probes described here. Real-time RT-PCR is a fast, sensitive and semi-automated method to quantitate the initial template number when appropriate conditions are established. Quantitation of the normalized bcr-abl expression may not only be helpful after allogeneic SCT for detection of early relapse in order to start DLIs and to control their effects. It should be possible to monitor the dynamic of the disease and the efficacy of any therapeutic regimen before and after SCT 22 by real-time RT-PCR. It will also enable a quality control of leukapheresis products collected for autologous SCT. For all these purposes it will however be necessary to evaluate realtime RT-PCR in a prospective setting of a large number of patients.
